Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC).

• DOI: 10.1200/jco.2011.29.15_suppl.4119
• Publication Date: 2017-02-23T13:58:03Z
• Authors: Y. Kang; A. Ohtsu; E. Van Cutsem; L. Roman; J. Nunes; C. Li; D. Otero; F. Rivera; G. Aprile; P. R. Pimentel Al...; M. H. Moehler; J. Wu; B. Langer; M. A. Shah
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

4119 Background: A difference in median overall survival (OS) of 2 months between treatment arms was observed AVAGAST, but the result not significant. However, significant differences OS regions were seen, with more benefit region poorer survival. Furthermore, multiple Cox-regression analysis for revealed 5 covariates prognostic value. simple index 3 risk groups (RG) created to test impact RG and on OS. Methods: Multiple Cox regression showed (apart from regional differences) outcome for: ECOG PS >1 (HR=1.95; p=0.0003), prior gastrectomy (0.66; 0.0005), bone mets (1.71; 0.0097), intestinal type histology (0.74; 0.003) peritoneal (1.39; 0.0015). 774 pts sorted by number negative factors present at baseline pooled into different RGs: low (no involved); moderate (1 covariate); high (>1 covariate). Because large impact, received a score 2. performed region. Results: Approx. 10% belonged RG, 30% remaining 60% RG. are shown table. Conclusions: Outside Asia, high-risk AGC may addition bev cisplatin/capecitabine. This predictive effect ≤1 factors, although there few 0 or 1 factors. The lack efficacy Asian cannot be explained baseline. Risk group Region Patients per arm (bev/pla) Hazard ratio 95% CI P value Low All 27/31 1.60 0.67–3.81 0.2869 Asia 8/17 2.38 0.50–11.32 0.2621 Europe 13/8 1.07 0.29–4.00 0.9170 Americas 6/6 2.62 0.24–29.02 0.4135 Moderate 101/108 0.96 0.68–1.37 0.8428 43/47 0.95 0.54–1.66 0.8611 43/39 1.23 0.72–2.10 0.4468 15/22 0.63 0.26–1.51 0.2967 High 259/248 0.80 0.65–0.98 0.0307 137/124 0.99 0.74–1.33 0.9604 68/78 0.59 0.41–0.85 0.0043 54/46 0.60 0.38–0.94 0.0246